The approval is supported by bioequivalence data assessing the once-daily extended-release formulation to twice-daily immediate-release ruxolitinib in healthy participants.

Indications span MF and PV in adults, plus acute/chronic GVHD in patients ≥12 years, positioning XR as a once-daily ...

FDA cleared once-daily ruxolitinib XR for MF, HU-refractory/intolerant PV, and steroid-refractory acute/chronic GVHD after ...

The agency approved Jakafi XR, known generically as ruxolitinib, to treat adults with intermediate- or high-risk myelofibrosis, polycythemia, or adults or children with graft-versus-host disease who ...

FluidCrystal® extended release formulation of zilucoplan achieved rapid and sustained pharmacodynamic inhibition of complement C5 in non-human primates, supporting at least once weekly dosing ...

The FDA approved an oral extended-release formulation of levodopa and carbidopa known as IPX203 (Crexont) to treat Parkinson's disease, Amneal Pharmaceuticals announced Wednesday. The treatment is a ...

WOODCLIFF LAKE, N.J. and SAN DIEGO, Nov. 30, 2015 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (ARNA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for ...

DUBLIN--(BUSINESS WIRE)--The "Extended Release Injectable Drugs" report has been added to ResearchAndMarkets.com's offering. Chronic conditions require drug administration over long periods of time, ...

Phase 2/3 trial data show VDPHL01, an oral non-hormonal extended-release minoxidil, improves hair growth and patient-reported outcomes in male pattern hair loss.